O'Reilly R A, Motley C H
Ann Intern Med. 1979 Jul;91(1):34-6. doi: 10.7326/0003-4819-91-1-34.
Eleven normal humans were studied to evaluate the reported interaction of racemic sodium warfarin and trimethoprim-sulfamethoxazole prospectively. Single oral doses of racemic warfarin, 1.5 mg/kg of body weight, were administered with and without 320 mg of trimethoprim and 1600 mg of sulfamethoxazole orally, beginning 7 d before the warfarin and continuing daily throughout the hypoprothrombinemia. Daily plasma samples were analyzed for one-stage prothrombin activity (Quick) and for warfarin content by high-pressure liquid chromatography. Transient cutaneous reactions developed in four of 11 subjects: a morbilliform rash in three (studies discontinued) and generalized pruritus in one. A highly significant augmentation of the warfarin effect on the mean one-stage prothrombin activity (P less than 0.03) occurred with trimethoprim-sulfamethoxazole, but no significant effect was found on the warfarin half-life (P greater than 0.5). It is concluded that trimethoprim-sulfamethoxazole interacts with racemic warfarin, possibly at a receptor-site locus.
为前瞻性评估已报道的消旋华法林钠与甲氧苄啶 - 磺胺甲恶唑之间的相互作用,对11名正常受试者进行了研究。在服用华法林前7天开始,每天口服1.5mg/kg体重的消旋华法林,同时口服320mg甲氧苄啶和1600mg磺胺甲恶唑,或不服用,在整个低凝血酶原血症期间持续每日给药。每天采集血浆样本,通过高压液相色谱法分析一期凝血酶原活性(Quick)和华法林含量。11名受试者中有4人出现短暂性皮肤反应:3人出现麻疹样皮疹(研究中断),1人出现全身性瘙痒。甲氧苄啶 - 磺胺甲恶唑使华法林对平均一期凝血酶原活性的作用显著增强(P<0.03),但对华法林半衰期无显著影响(P>0.5)。结论是,甲氧苄啶 - 磺胺甲恶唑与消旋华法林相互作用,可能作用于受体位点。